Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood injection restore lost smell? new study aims to find out

NCT ID NCT07473830

Symptom relief Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether injecting a person's own platelet-rich plasma (PRP) into the nose can help restore smell in adults who have had smell loss for more than 6 months due to aging or head injury. Thirty participants will receive three PRP injections over four weeks and be followed for six months. The main goal is to see if enough people experience a meaningful improvement in their sense of smell.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Adults with persistent (\>6 months) non-tumoural olfactory dysfunction: age-related degenerative olfactory dysfunction (DOD) or post-traumatic olfactory dysfunction (DOPT). * Objective olfactory impairment confirmed by Sniffin' Sticks Test (TDI ≤ 30.5/48). * MRI within the last 6 months after onset excluding tumoural etiology or central cause. * Normal nasal endoscopy. * Affiliated to a social security system (or equivalent). * Written informed consent. Exclusion Criteria * Inflammatory rhinosinus disease (e.g., nasal polyposis) or granulomatosis with polyangiitis. * Coagulation disorder. * Brain radiotherapy history or ongoing chemotherapy. * Olfactory disorder temporally linked to SARS-CoV-2 infection (delay \<1 month). * History of sinus or skull base surgery (except septoplasty/turbinoplasty/rhinoseptoplasty). * Therapeutic-dose anticoagulants. * Refusal to discontinue chronic NSAID use if applicable. * Pregnancy/labor/breastfeeding. * Vulnerable persons (deprived of liberty; legal protection; etc.). * Participation in another interventional study with ongoing exclusion period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related degenerative olfactory dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anosmia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age-related degenerative olfactory dysfunction Anosmia Hyposmia Olfactory dysfunction Post-traumatic olfactory dysfunction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Lyon Sud

    Pierre-Bénite, 69310, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.